Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.69 |
| ▸ | GAK | O14976 | 3/20 | 0.56 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.56 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.56 |
| ▸ | STK16 | O75716 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.56 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.56 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.56 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.56 |
| ▸ | CCNC | P24863 | 2/20 | 0.55 |
| ▸ | CDK8 | P49336 | 2/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4538471 | 0.86 | ALK (0.62) | SLC22A12GAKEPHB6RIPK2STK16 | |
| SCHEMBL28221632 | 0.81 | HTT (0.60) | SLC22A12GAKEPHB6RIPK2STK16 | |
| SCHEMBL25053127 | 0.80 | HTR1A (0.70) | SLC22A12RIPK2ACVR1CDK8HTR1A | |
| SCHEMBL23948102 | 0.79 | CDK8 (0.60) | SLC22A12GAKRIPK2ACVR1CCNC | |
| SCHEMBL12095894 | 0.77 | SLC22A12 (0.58) | SLC22A12GAKEPHB6RIPK2STK16 | |
| SCHEMBL24151556 | 0.77 | ALK (0.78) | SLC22A12GAKEPHB6RIPK2STK16 | |
| SCHEMBL2621803 | 0.77 | SLC22A12 (0.55) | SLC22A12GAKEPHB6RIPK2STK16 | |
| SCHEMBL23999421 | 0.76 | IP6K1 (0.46) | SLC22A12CCNCCDK8HTR1AADRA1D | |
| SCHEMBL25520952 | 0.76 | MAPKAPK2 (0.52) | SLC22A12ACVR1CCNCCDK8HTR1A | |
| SCHEMBL2621805 | 0.76 | CCNC (0.62) | SLC22A12GAKEPHB6RIPK2STK16 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112955432-B | Fused aromatic ring derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-2560967-B1 | Heterocyclic carboxylic acid amides as PDK1 inihibitors | BOEHRINGER INGELHEIM INT (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-8575203-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-8575203-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| WO-2011131741-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | WO | disclosed |
| WO-2010026121-A1 | BICYCLIC KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| US-20080214455-A1 | Novel Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| EP-1879563-A4 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1879563-A2 | NOVEL CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006132739-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | CCNB1, MKI67, CCNA1 | SLC22A12 960/4885GAK 1429/4885EPHB6 1962/4885 |
| US-20080214455-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | SLC22A12 4103/4885GAK 1413/4885EPHB6 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.